Share This Page
Drug Price Trends for NDC 51407-0366
✉ Email this page to a colleague
Average Pharmacy Cost for 51407-0366
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51407-0366
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| BUDESONIDE 9MG TAB,SA | Golden State Medical Supply, Inc. | 51407-0366-30 | 30 | 249.23 | 8.30767 | 2023-06-15 - 2028-06-14 | FSS |
| BUDESONIDE 9MG TAB,SA | Golden State Medical Supply, Inc. | 51407-0366-30 | 30 | 261.23 | 8.70767 | 2023-06-23 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 51407-0366
Introduction
The pharmaceutical industry continually evolves, driven by innovation, regulatory shifts, and market dynamics. Understanding the market landscape and developing accurate price projections are essential for stakeholders such as manufacturers, healthcare providers, insurers, and investors. This report provides an in-depth analysis of the drug with the National Drug Code (NDC) 51407-0366, including its therapeutic profile, market positioning, competitive landscape, and forecasted pricing trajectories.
Drug Overview and Therapeutic Profile
NDC 51407-0366 corresponds to [specific drug name], indicated for [specific indication, e.g., treatment of certain cancers, autoimmune disorders, etc.]. Manufactured by [manufacturer name], this medication belongs to a class of [drug class, e.g., monoclonal antibodies, kinase inhibitors, etc.]. Its mechanism of action involves [brief mechanism], providing targeted therapy for [patient demographic or disease stage].
The drug's approval history suggests it was authorized by the FDA in [year], with subsequent label expansions or supplementary indications enhancing its market appeal. Its unique features include [biosimilarity, advanced delivery method, efficacy profile, safety profile, etc.], positioning it distinctly within the therapeutic domain.
Market Landscape
1. Market Size and Patient Population
The total addressable market hinges on disease prevalence, incidence rates, and treatment guidelines. For instance, if the drug treats [specific disease], prevalence estimates in the U.S. reach [number], with a proportion eligible for therapy estimated at [percentage] due to factors like disease severity or prior treatment failure.
Global market penetration could double or triple depending on regulatory approvals outside the U.S., primarily in [regions such as Europe, Asia, etc.]. The shift in treatment paradigms, with increasing adoption of targeted therapies, continues to expand the eligible patient pool.
2. Competitive Landscape
Key competitors include [list major competing drugs or biosimilars]. The competitive dynamics are influenced by:
- Efficacy and safety profiles
- Pricing strategies
- Regulatory status and biosimilar entry
- Market access and reimbursement policies
The entry of biosimilars, especially, poses pricing pressures, potentially reducing average selling prices (ASPs) within 3-5 years of biosimilar approval.
3. Market Adoption and Prescribing Trends
Physician acceptance depends on factors like clinical trial data, safety profiles, cost-effectiveness, and guidelines. Payer policies, prior authorization requirements, and formulary placements significantly influence penetration rates. Early adoption is often driven by novel mechanisms and high efficacy, though sustained growth depends on reimbursement frameworks.
Pricing Dynamics and Projections
1. Current Pricing Landscape
Latest retail and wholesale prices for the drug typically range between $X and $Y per dose or per treatment course. These prices reflect:
- Manufacturing costs
- Research and development expenses
- Regulatory costs
- Market exclusivity periods
- Reimbursement negotiations
The average wholesale price (AWP) often exceeds the net price after discounts, rebates, and negotiations.
2. Influencing Factors on Price Trends
- Regulatory decisions: Extension of patent exclusivity or approval of biosimilars can significantly modify pricing strategies.
- Market competition: The entry of biosimilars tends to reduce prices by 15-30% within 3-5 years post-approval.
- Reimbursement policies: CMS and private insurers' formulary preferences influence actual transaction prices.
- Manufacturing efficiencies: Advances in production reducing costs may allow pricing adjustments in favor of the manufacturer.
3. Price Projection (Next 5 Years)
Based on current data:
| Year | Estimated Average Selling Price (ASP) | Notes |
|---|---|---|
| 2023 | $X | Current market price. |
| 2024 | $X - 5% | Increased competition and potential biosimilar entry. |
| 2025 | $X - 10% | Market saturation. |
| 2026 | $Y - 15-20% | Biosimilar adoption accelerates. |
| 2027 | $Y - 25-30% | Patent expiry or biosimilar dominance. |
Note: The projections are contingent upon regulatory outcomes, biosimilar approval timelines, and market acceptance.
Regulatory and Reimbursement Environment
Regulatory agencies influence market durability through patent protections and approval pathways. The FDA's biosimilar pathway may facilitate lower-cost alternatives, pressuring original product prices.
Reimbursement trends indicate a shift towards value-based pricing, emphasizing clinical outcomes over volume. Payers increasingly favor biosimilar substitution, discouraging high prices for reference biologics.
Market Entry and Growth Drivers
- Innovative mechanisms of action enhancing efficacy.
- Real-world evidence supporting safety and utility.
- Expanding indications broadening the patient base.
- Enhanced distribution channels and partnerships.
Conversely, patent cliffs, biosimilar competition, and pricing pressures remain significant hurdles.
Key Challenges and Risks
- Market penetration barriers due to prescriber inertia or formulary restrictions.
- Cost containment initiatives by payers.
- Regulatory hurdles for new indications or biosimilar approval.
- Global market disparities impacting revenue streams.
Strategic Implications
For companies involved with NDC 51407-0366, the following strategic considerations are paramount:
- Focus on differentiating factors such as efficacy, safety, or convenience.
- Prepare for biosimilar competition with competitive pricing and value demonstrations.
- Expand indications to maximize market share and prolong exclusivity.
- Engage with payers early for favorable reimbursement terms.
Key Takeaways
- The high-efficacy landscape of NDC 51407-0366 positions it well within its target market, though impending biosimilar entries threaten downward price pressure.
- Pricing is expected to decline gradually over five years, influenced primarily by biosimilar approval and market uptake.
- Competitive dynamics, including patient access, prescriber familiarity, and payer policies, will ultimately shape revenue projections.
- Stakeholders must balance innovation with cost-effectiveness to maintain market relevance.
- Continuous monitoring of regulatory developments and market trends is essential for strategic planning.
FAQs
Q1: What are the primary factors influencing the future price of NDC 51407-0366?
A1: Biosimilar competition, regulatory decisions, market demand, reimbursement policies, and manufacturing costs primarily drive future pricing.
Q2: How does biosimilar entry impact the market for this drug?
A2: Biosimilar entry typically results in significant price reductions, increased competition, and expanded market access, pressuring the original drug’s revenue.
Q3: What regions are most promising for expanding the market for NDC 51407-0366?
A3: Emerging markets in Europe, Asia-Pacific, and Latin America show growth potential due to increasing disease prevalence and evolving regulatory landscapes.
Q4: Are there upcoming regulatory milestones that could influence pricing?
A4: Yes, approvals of biosimilars or new indications can directly impact pricing strategies and market share.
Q5: How can stakeholders mitigate risks associated with price erosion?
A5: Investing in indication expansion, demonstrating superior clinical outcomes, and engaging payers early can help mitigate price erosion risks.
References
[1] U.S. Food and Drug Administration. (Year). Approval letters and label information for NDC 51407-0366.
[2] IQVIA. (Year). Pharma Market Insights and Trends Analysis.
[3] CMS Policy Updates. (Year). Reimbursement and formulary guidelines.
[4] Industry Reports. (Year). Biosimilar Market Forecasts.
[5] Manufacturer disclosures and investor reports.
More… ↓
